The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.

Bibliographic Details
Main Authors:	J Picot, K Cooper, J Bryant, AJ Clegg
Format:	Article
Language:	English
Published:	NIHR Journals Library 2011-12-01
Series:	Health Technology Assessment
Online Access:	https://doi.org/10.3310/hta15410

id	doaj-49d95a8c4a1a4095aea347b345928e7a
record_format	Article
spelling	doaj-49d95a8c4a1a4095aea347b345928e7a2020-11-24T22:03:18ZengNIHR Journals LibraryHealth Technology Assessment1366-52782011-12-01154110.3310/hta15410The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.J Picot0K CooperJ BryantAJ CleggSouthampton Health Technology Assessments Centre (SHTAC), Southampton, UKhttps://doi.org/10.3310/hta15410
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	J Picot K Cooper J Bryant AJ Clegg
spellingShingle	J Picot K Cooper J Bryant AJ Clegg The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation. Health Technology Assessment
author_facet	J Picot K Cooper J Bryant AJ Clegg
author_sort	J Picot
title	The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
title_short	The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
title_full	The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
title_fullStr	The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
title_full_unstemmed	The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
title_sort	clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
publisher	NIHR Journals Library
series	Health Technology Assessment
issn	1366-5278
publishDate	2011-12-01
url	https://doi.org/10.3310/hta15410
work_keys_str_mv	AT jpicot theclinicaleffectivenessandcosteffectivenessofbortezomibandthalidomideincombinationregimenswithanalkylatingagentandacorticosteroidforthefirstlinetreatmentofmultiplemyelomaasystematicreviewandeconomicevaluation AT kcooper theclinicaleffectivenessandcosteffectivenessofbortezomibandthalidomideincombinationregimenswithanalkylatingagentandacorticosteroidforthefirstlinetreatmentofmultiplemyelomaasystematicreviewandeconomicevaluation AT jbryant theclinicaleffectivenessandcosteffectivenessofbortezomibandthalidomideincombinationregimenswithanalkylatingagentandacorticosteroidforthefirstlinetreatmentofmultiplemyelomaasystematicreviewandeconomicevaluation AT ajclegg theclinicaleffectivenessandcosteffectivenessofbortezomibandthalidomideincombinationregimenswithanalkylatingagentandacorticosteroidforthefirstlinetreatmentofmultiplemyelomaasystematicreviewandeconomicevaluation AT jpicot clinicaleffectivenessandcosteffectivenessofbortezomibandthalidomideincombinationregimenswithanalkylatingagentandacorticosteroidforthefirstlinetreatmentofmultiplemyelomaasystematicreviewandeconomicevaluation AT kcooper clinicaleffectivenessandcosteffectivenessofbortezomibandthalidomideincombinationregimenswithanalkylatingagentandacorticosteroidforthefirstlinetreatmentofmultiplemyelomaasystematicreviewandeconomicevaluation AT jbryant clinicaleffectivenessandcosteffectivenessofbortezomibandthalidomideincombinationregimenswithanalkylatingagentandacorticosteroidforthefirstlinetreatmentofmultiplemyelomaasystematicreviewandeconomicevaluation AT ajclegg clinicaleffectivenessandcosteffectivenessofbortezomibandthalidomideincombinationregimenswithanalkylatingagentandacorticosteroidforthefirstlinetreatmentofmultiplemyelomaasystematicreviewandeconomicevaluation
_version_	1725832191450021888

The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.

Similar Items